Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2006-3-20
pubmed:abstractText
The sphingolipid ceramide has been recognized as an important mediator in the apoptotic machinery, and its efficient conversion to glucosylceramide has been associated with multidrug resistance. Therefore, inhibitors of glucosylceramide synthase are explored as tools for treatment of cancer. In this study, we used D,L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol to sensitize Neuro-2a murine neuroblastoma cells to the microtubule-stabilizing agent paclitaxel. This treatment resulted in a synergistic inhibition of viable cell number increase, which was based on a novel mechanism: (a) After a transient mitotic arrest, cells proceeded through an aberrant cell cycle resulting in hyperploidy. Apoptosis also occurred but to a very limited extent. (b) Hyperploidy was not abrogated by blocking de novo sphingolipid biosynthesis using ISP-1, ruling out involvement of ceramide as a mediator. (c) Cyclin-dependent kinase 1 and 2 activities were synergistically decreased on treatment. In conclusion, instead of inducing apoptosis through ceramide accumulation, D,L-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol by itself affects cell cycle-related proteins in paclitaxel-arrested Neuro-2a cells resulting in aberrant cell cycle progression leading to hyperploidy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1535-7163
pubmed:author
pubmed:issnType
Print
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
593-601
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:16546973-Animals, pubmed-meshheading:16546973-Antineoplastic Agents, pubmed-meshheading:16546973-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:16546973-Apoptosis, pubmed-meshheading:16546973-CDC2 Protein Kinase, pubmed-meshheading:16546973-Cell Cycle, pubmed-meshheading:16546973-Ceramides, pubmed-meshheading:16546973-Cyclin-Dependent Kinase 2, pubmed-meshheading:16546973-Down-Regulation, pubmed-meshheading:16546973-Drug Resistance, Neoplasm, pubmed-meshheading:16546973-Fatty Acids, Monounsaturated, pubmed-meshheading:16546973-Lipid Metabolism, pubmed-meshheading:16546973-Mice, pubmed-meshheading:16546973-Morpholines, pubmed-meshheading:16546973-Neuroblastoma, pubmed-meshheading:16546973-Paclitaxel, pubmed-meshheading:16546973-Polyploidy, pubmed-meshheading:16546973-Sphingolipids
pubmed:year
2006
pubmed:articleTitle
PDMP sensitizes neuroblastoma to paclitaxel by inducing aberrant cell cycle progression leading to hyperploidy.
pubmed:affiliation
Department of Cell Biology, Section Membrane Cell Biology, University Medical Center Groningen, A. Deusinglaan 1, 9713 AV Groningen, the Netherlands.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't